Market Intelligence, Clinical Progress, and High-Purity Reagents for Innate Immunity Modulation.
TarMart Solution Ecosystem & Network Targets
Comprehensive reagent toolkit for TLR2 heterodimer drug discovery. Select your component below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TLR2 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <0.1 EU/μg. Sequence Verified. HEK293 expressed, native glycosylation. |
View TLR2 Products |
| Gene Delivery | TLR2 Lentivirus Particles (pLenti-ORF) High titer (>10^8 TU/mL) for stable NF-κB reporter cell line construction. Preserves native conformation. |
View TLR2 Products |
| Benchmark Ab | Anti-TLR2 (Recombinant Positive Control) Sequence Verified. |
View TLR2 Products |
| Validator | TLR2 siRNA Set For knockdown verification and specificity checks. |
View TLR2 Products |
| Heterodimer Partner 1 | TLR1 ECD-Fc Protein For TLR2/TLR1 (Pam3CSK4) complex formation studies. |
View TLR1 Products |
| Heterodimer Partner 2 | TLR6 ECD-Fc Protein For TLR2/TLR6 (Pam2CSK4) discrimination assays. |
View TLR6 Products |
| Co-receptor | CD14 Recombinant Protein Soluble co-receptor for ligand presentation enhancement. |
View CD14 Products |
| Related Target A | TLR4 Synergistic pattern recognition pathway and cross-screening counter-target. |
View TLR4 Products |
| Related Target B | MYD88 Crucial downstream adaptor protein for intracellular signaling cascades. |
View MYD88 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimer Selectivity (TLR1 vs TLR6) | Matched Human/Mouse/Cyno TLR2, TLR1, TLR6 ECD proteins with theoretical MW verified by Mass Spec; enables pairwise SPR screening. |
| Endotoxin Contamination Artifacts | Ultra-low Endotoxin grade (<0.1 EU/μg) via LAL chromogenic assay; essential for TLR2 (lipopeptide-sensitive) assay validity. |
| Conformational Epitope Preservation | HEK293 mammalian expression preserving native glycosylation and disulfide bonds critical for LRR domain folding. |
| Cross-species Translation (Human/Mouse/Cyno) | Ortholog protein panel (Human, Cyno, Mouse, Rat) with identical domain boundaries for cross-reactivity assessment. |
| Lack of Positive Controls | Recombinant anti-TLR2 benchmark antibody (sequence verified) included for assay validation. |
| Off-Target / Specificity Verification | TLR2-specific siRNA sets included for knockdown validation; ensures phenotype specificity. |
Live TLR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The TLR2 therapeutic landscape has shifted dramatically from broad immunosuppression toward precision modulation. Following setbacks in sepsis indication due to excessive immunosuppression, current R&D focuses on selective TLR2/TLR6 versus TLR2/TLR1 heterodimer inhibition for autoimmune indications (rheumatoid arthritis, psoriasis) and atherosclerosis. First-generation monoclonal antibodies such as OPN-305 have established proof-of-mechanism in ischemia/reperfusion injury and myelodysplastic syndromes. The next wave targets chronic inflammatory indications—including NASH and autoimmune pathologies—and explores combination regimens with immune checkpoint inhibitors to remodel the tumor microenvironment. Agonists are also being developed as next-generation vaccine adjuvants and immunomodulators for oncology. Key challenges include avoiding systemic cytokine storms and achieving tissue-specific delivery.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonist) | Omeros, Boehringer Ingelheim, Opsona Therapeutics, Janssen | Autoimmune, Ischemia-Reperfusion, Atherosclerosis, MDS | High-affinity binding and heterodimer selectivity; Need high-purity ECD-Fc proteins and epitope mapping via domain swapping. |
| Small Molecule Antagonist | Novartis, Takeda | Rheumatoid Arthritis, Pain, Inflammation | Heterodimer Selectivity Panel (TLR2/TLR1 vs TLR2/TLR6 discrimination using purified ECDs). |
| Agonist (Peptide/Lipid) | Various Biotechs, Academic Consortia | Vaccine Adjuvant, Oncology, Infectious Disease | Functional activation assays; Need full-length TLR2 lentivirus lines for stable cell-based reporter assays. |
| Decoy Peptide / Synthetic Lipopeptide | Academic / Boehringer Ingelheim | Inflammatory Bowel Disease, Infectious Disease | Ligand competition assay (Pam3CSK4/Pam2CSK4 displacement with luminescent readout); Need high-purity TLR2 ECD-Fc. |